Drawing for HOLOGRAPHIC GENOME SEQUENCING

USPTO serial 90002945

HOLOGRAPHIC GENOME SEQUENCING

Reviewed by CopyMark Law Group

Status 601
Filing date
Status date
Registration date
—
Examiner
PEISECKI, MARK A
Law office
TMEG LAW OFFICE 105 - EXAMINING ATTORNEY ASSIGNED

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with HOLOGRAPHIC GENOME SEQUENCING?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
042DNA analysis services for scientific research purposes; DNA analysis services to determine paternity; DNA screening for scientific research purposes; Genetic mapping for scientific purposes; Genetic testing for scientific research purposes; Genetic testing of laboratory animals for research purposes; Genome amplification; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Drug, alcohol and DNA screening for forensic research purposes; Providing information in the field of plant genetics research resources; Providing laboratory research services in the field of gene expression, namely, cancer biology; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Providing scientific research information in the field of genetics; Providing scientific research information in the field of genomics; Providing scientific research information in the field of holographic genome sequencing; Providing scientific research information in the field of holographic genome testing; Providing scientific research information in the field of gene splicing; Providing scientific research information in the field of holographic gene splicing; Providing scientific research information in the field of decoding genes; Providing scientific research information in the field of decoding genomes; Providing scientific research information in the field of decoding DNA; Providing scientific research information in the field of holographic genome decoding; Providing scientific research information in the field of holographic genomic decoding; Providing scientific research information in the field of genome decoding holography; Scientific research consulting in the field of genetics; Scientific research consulting in the field of genomics; Scientific research consulting in the field of holographic genome sequencing; Scientific research consulting in the field of holographic genome testing; Scientific research consulting in the field of gene splicing; Scientific research consulting in the field of holographic gene splicing; Scientific research consulting in the field of decoding genes; Scientific research consulting in the field of decoding genomes; Scientific research consulting in the field of decoding DNA; Scientific research consulting in the field of holographic genome decoding; Scientific research consulting in the field of holographic genomic decoding; Scientific research consulting in the field of genome decoding holography; Scientific research in the field of genetics and genetic engineering; Scientific research in the field of genetics; Scientific research in the field of genomics; Scientific research in the field of holographic genome sequencing; Scientific research in the field of holographic genome testing; Scientific research in the field of gene splicing; Scientific research in the field of holographic gene splicing; Scientific research in the field of decoding genes; Scientific research in the field of decoding genomes; Scientific research in the field of decoding DNA; Scientific research in the field of holographic genome decoding; Scientific research in the field of holographic genomic decoding; Scientific research in the field of genome decoding holography; Structural and functional analysis of genomes; Testing, inspection, research, or development of pharmaceutical preparations for gene therapyACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 26, 2021MAB1ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT—
Apr 26, 2021ABN1ABANDONMENT - EXPRESS MAILED—
Mar 22, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 22, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 22, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 22, 2020GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 22, 2020GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 22, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 16, 2020DOCKASSIGNED TO EXAMINER—
Jul 13, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 18, 2020NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance